Edition:
United Kingdom

Ionis Pharmaceuticals Inc (IONS.OQ)

IONS.OQ on NASDAQ Stock Exchange Global Select Market

45.13USD
15 Oct 2018
Change (% chg)

$0.13 (+0.29%)
Prev Close
$45.00
Open
$45.07
Day's High
$45.82
Day's Low
$44.55
Volume
280,557
Avg. Vol
365,136
52-wk High
$65.51
52-wk Low
$39.08

Select another date:

Wed, Oct 10 2018

BRIEF-Ionis Pharmaceuticals Enters New Collaboration With Partner

* IONIS ENTERS NEW COLLABORATION WITH PARTNER TO DEVELOP IONIS-FB-L RX FOR COMPLEMENT-MEDIATED DISEASES

Akcea Therapeutics genetic disease treatment gets FDA approval

Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

Akcea Therapeutics genetic disease treatment gets FDA approval

Oct 5 Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration.

FDA declines to approve Akcea-Ionis genetic disease drug

The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

UPDATE 1-FDA declines to approve Akcea/Ionis genetic disease drug

Aug 27 The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease that causes fat accumulation in the blood.

U.S. FDA declines to approve Akcea/Ionis genetic disease drug

Aug 27 The U.S. Food and Drug Administration on Monday declined to approve a drug from Akcea Therapeutics Inc and Ionis Pharmaceuticals that aims to treat a genetic disease which causes fat accumulation in the blood.

BRIEF-Ionis Reports Q1 Total Revenue Of $144 Mln Vs $116 Mln

* FOR Q1 OF 2018, BASIC AND DILUTED NET LOSS PER SHARE WERE $0.01 Source text for Eikon: Further company coverage:

Biogen boosts investment in neurology with $1 billion Ionis deal

Biogen Inc struck a $1 billion neurology drug development deal with Ionis Pharmaceuticals on Friday, expanding a partnership that developed the company's potential blockbuster drug for spinal muscular atrophy.

BRIEF-Biogen And Ionis Expand Strategic Collaboration To Develop Drug Candidates For A Broad Range Of Neurological Diseases

* BIOGEN AND IONIS EXPAND STRATEGIC COLLABORATION TO DEVELOP DRUG CANDIDATES FOR A BROAD RANGE OF NEUROLOGICAL DISEASES

UPDATE 2-Biogen boosts investment in neurology with $1 bln Ionis deal

* Comprises equity investment in Ionis plus upfront payment (Adds background, share movement)

Select another date: